SuperbugsCompound to help combat antibiotic-resistant superbugs

Published 14 February 2012

Chemists have created a compound that makes existing antibiotics sixteen times more effective against recently discovered antibiotic-resistant “superbugs”

North Carolina State University chemists have created a compound that makes existing antibiotics sixteen times more effective against recently discovered antibiotic-resistant “superbugs.”

These so-called superbugs are actually bacterial strains that produce an enzyme known as New Delhi metallo-β-lactamase (NDM-1). Bacteria that produce this enzyme are practically impervious to antibiotics because NDM-1renders certain antibiotics unable to bind with their bacterial targets. Since NDM-1 is found in Gram-negative bacteria like K. pneumoniae, which causes pneumonia, urinary tract, and other common hospital-acquired infections, it is of particular concern.

“To begin with, there are fewer antibiotic options for treating infections caused by Gram-negative bacteria than for those caused by Gram-positive bacteria,” says Dr. Roberta Worthington, NC State research assistant professor of chemistry. “Gram-negative bacteria with the NDM-1 enzyme effectively neutralize the few weapons we have in our arsenal, making them especially difficult, if not impossible, to treat with existing antibiotic therapy.”

A North Carolina State University release reports that previously, NC State chemist Dr. Christian Melander had found that a compound derived from a class of molecules known as 2-aminoimidazoles “recharged” existing antibiotics, making them effective against Gram-positive antibiotic-resistant bacteria like the Staphylococcus strain MRSA. So Melander, Worthington, and graduate students Cynthia Bunders and Catherine Reed set to work on a variety of the compound that might prove similarly effective against their Gram-negative brethren.

In a paper published in ACS Medicinal Chemistry Letters, Worthington and Melander describe a compound that, when used in conjunction with the antibiotic imipenem, increased the antibiotic’s effectiveness against the antibiotic-resistant K. pneumoniae 16-fold. The researchers believe that these early results are very promising for future treatments.

“We’ve demonstrated that we have the ability to take out the scariest superbug out there,” Melander says.

“Hopefully further research will allow us to make the compound even more effective, and make these infections little more than a nuisance.”

The research was funded by the National Institutes of Health and the Jimmy V Foundation. The Department of Chemistry is part of NC State’s College of Physical and Mathematical Sciences.

— Read more in Roberta J. Worthington et al., “Small Molecule Suppression of Carbapenem Resistance in NDM-1 Producing Klebsiella pneumonia,” ACS Medicinal Chemistry Letters (4 February 2012) (DOI: 10.1021/ml200290p)